trending Market Intelligence /marketintelligence/en/news-insights/trending/vaqvg5r4yb02z9nk0eaxya2 content esgSubNav
In This List

Eisai epilepsy drug gets US FDA priority review for expanded use in children

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Eisai epilepsy drug gets US FDA priority review for expanded use in children

The U.S. Food and Drug Administration granted priority review status to Eisai Co. Ltd.'s antiepileptic drug Fycompa.

The Japanese drugmaker filed a supplemental new drug application to expand the use of Fycompa, also known as perampanel, to include treating children ages 2 to 12 with partial onset seizures or primary generalized tonic-clonic seizures.

Partial onset seizures start in only one side of a patient's brain and are more subtle and harder to spot. Tonic-clonic seizures, also known as grand mal seizures, affect the entire brain and may cause loss of consciousness and convulsions.

Last year, Fycompa was approved by the U.S. FDA as a single treatment to treat certain seizures in patients aged 12 and older with epilepsy.